Anti-human CD45RC antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12168694-B2
Application number	US-201917277511-A
Country	US
Kind code	B2
Filing date	Sep 20, 2019
Priority date	Sep 21, 2018
Publication date	Dec 17, 2024
Grant date	Dec 17, 2024

Abstract

Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RC high -related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

First claim

The invention claimed is:

1. An isolated anti-human CD45RC antibody or binding fragment thereof, wherein said antibody or binding fragment thereof comprises:
(a) a heavy chain variable region (HCVR) which comprises the following three complementary-determining regions (CDRs):
(i) V H -CDR1 of sequence SEQ ID NO: 1;
(ii) V H -CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 11, 100, 116, 117, 118 and 119; and
(iii) V H -CDR3 of sequence SEQ ID NO: 3; and

(b) a light chain variable region (LCVR) which comprises the following three CDRs:
(i) V L -CDR1 with a sequence selected from the group consisting of sequences SEQ ID NO: 15 (SASSSVS-X-YMH) and SEQ ID NO: 18 (RASSSVS-X-YMH), wherein X is absent or is selected from the group consisting of Asn (N), Ser(S) and Gly (G);
(ii) V L -CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs: 16, 19, 20, 22, 111, 120 and 127; and
(iii) V L -CDR3 with a sequence selected from the group consisting of sequences SEQ ID NOs: 17 and 21.

2. The isolated antibody or binding fragment thereof according to claim 1 , wherein said antibody or binding fragment thereof comprises a combination of 3 HCVR's CDRs and 3 LCVR's CDRs as set forth the table below:

CDRs'
V H -
V H -
V H -
V L -
V L -
V L -

combination #
CDR1
CDR2
CDR3
CDR1
CDR2
CDR3

 #1
1
4
3
15
16
17

 #2
1
4
3
18
16
17

 #3
1
4
3
18
19
17

 #4
1
4
3
18
20
17

 #5
1
4
3
18
19
21

 #6
1
4
3
18
22
17

 #7
1
5
3
15
16
17

 #8
1
5
3
18
16
17

 #9
1
5
3
18
19
17

 #10
1
5
3
18
20
17

 #11
1
5
3
18
19
21

 #12
1
5
3
18
22
17

 #13
1
6
3
15
16
17

 #14
1
6
3
18
16
17

 #15
1
6
3
18
19
17

 #16
1
6
3
18
20
17

 #17
1
6
3
18
19
21

 #18
1
6
3
18
22
17

 #19
1
7
3
15
16
17

 #20
1
7
3
18
16
17

 #21
1
7
3
18
19
17

 #22
1
7
3
18
20
17

 #23
1
7
3
18
19
21

 #24
1
7
3
18
22
17

 #25
1
8
3
15
16
17

 #26
1
8
3
18
16
17

 #27
1
8
3
18
19
17

 #28
1
8
3
18
20
17

 #29
1
8
3
18
19
21

 #30
1
8
3
18
22
17

 #31
1
9
3
15
16
17

 #32
1
9
3
18
16
17

 #33
1
9
3
18
19

Assignees

• Inst Nat Sante Rech Med
• Univ Nantes
• Ct Hospitalier Universitaire Nantes
• Univ Nantes

Inventors

• Guillonneau Carole
• Anegon Ignacio

Classifications

• A61P37/06 Primary

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title